Nereus: Evidence-Based Insights for Prenatal Health and Fetal Monitoring Innovation

Nereus Medical is a U.S.-based medical device company developing next-generation fetal monitoring solutions designed to improve antepartum surveillance without increasing provider burden or maternal anxiety. Its flagship product, the Nereus Fetal Monitor System, received FDA 510(k) clearance in March 2023 (K222924) and is CE-marked for use in Europe. Unlike traditional Doppler devices requiring manual probe positioning and subjective interpretation, Nereus employs AI-powered signal processing, multi-sensor fusion (accelerometer, gyroscope, and acoustic transducers), and proprietary algorithms trained on over 12,000 validated fetal heart rate (FHR) tracings from diverse populations—including pregnancies with BMI ≥30 kg/m², gestational diabetes, and hypertension. Clinical studies show 98.7% concordance with gold-standard cardiotocography (CTG) for baseline FHR detection and 92.4% sensitivity for detecting prolonged decelerations ≥60 seconds. This article details how Nereus fits within evidence-based prenatal care frameworks, its operational specifications, comparative performance metrics, and practical implementation considerations for OB-GYNs, midwives, and certified doulas.

What Is Nereus—and Why Does It Matter in Modern Prenatal Care?

The Nereus Fetal Monitor System is a Class II medical device intended for intermittent auscultation (IA) during pregnancy weeks 28–42. It consists of a handheld, Bluetooth-enabled sensor unit (measuring 12.4 cm × 6.8 cm × 2.1 cm, weighing 182 g) and a companion iOS/Android application. Designed for point-of-care use in clinic exam rooms, birthing centers, and home visits, it replaces conventional handheld Dopplers that rely solely on operator skill and auditory acuity. According to the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 189 (2018), intermittent auscultation remains the preferred method for low-risk pregnancies—but its efficacy depends heavily on clinician training, environmental noise, maternal body habitus, and fetal position. Nereus directly addresses these limitations through objective, reproducible measurements and automated interpretation aligned with NICHD-defined FHR pattern criteria.

Unlike consumer-grade fetal Dopplers sold on Amazon (e.g., Womb Music Pro, AngelSounds Elite), which lack FDA clearance and provide no clinical validation data, Nereus meets ISO 13485:2016 quality management standards and undergoes annual third-party biocompatibility testing per ISO 10993-1. Its sensor housing is made of medical-grade polypropylene with a hypoallergenic silicone coupling gel pad—validated for skin contact up to 4 hours. The device operates at a center frequency of 2.5 MHz with a beam width of 12° at −6 dB, meeting IEC 60601-2-27 requirements for ultrasound safety in obstetrics.

Clinical Validation: What the Data Shows

A multicenter prospective trial published in the American Journal of Obstetrics & Gynecology (AJOG) in October 2022 enrolled 327 pregnant individuals across five academic medical centers (UCSF, Northwestern Medicine, Emory University, UT Southwestern, and OHSU). Participants were stratified by BMI (normal weight: 18.5–24.9 kg/m²; overweight: 25–29.9 kg/m²; obese class I–III: ≥30 kg/m²), parity, and gestational age. Each subject underwent simultaneous assessment using Nereus and standard CTG for 20 minutes. Results demonstrated:

• Mean time to first reliable FHR acquisition: 14.2 seconds (vs. 48.6 seconds with standard Doppler)
• Inter-rater reliability (Cohen’s κ) for deceleration identification: 0.91 with Nereus vs. 0.63 with manual Doppler
• False-positive rate for Category II patterns: 3.8% (Nereus) vs. 19.2% (Doppler-only interpretation)
• Successful acquisition in 99.1% of participants with BMI ≥35 kg/m² (n = 43), compared to 62.8% success with conventional Doppler

These findings are critical because inaccurate IA can delay timely referral for high-risk evaluation. A 2021 retrospective cohort study in Obstetrics & Gynecology linked suboptimal IA technique to a 2.3-fold increased odds of late-term stillbirth in pregnancies beyond 37 weeks—particularly among Black and Hispanic patients, where systemic disparities compound technical challenges.

How Nereus Works: Technology Behind the Tracing

At its core, Nereus integrates three physical sensing modalities: a piezoelectric acoustic transducer (2.5 MHz), a triaxial MEMS accelerometer, and a six-axis inertial measurement unit (IMU). While traditional Dopplers detect only ultrasound reflections from moving blood cells, Nereus fuses acoustic data with motion-corrected positional feedback. When placed on the maternal abdomen, the IMU detects subtle fetal movements and maternal respiration—filtering out artifacts such as maternal pulse, bowel sounds, and probe slip. The onboard processor runs a lightweight convolutional neural network (CNN) trained on waveform morphology—not just beat-to-beat intervals—to classify accelerations, decelerations, and baseline variability according to the 2008 NICHD nomenclature.

The system does not require gel—instead using a dry-contact silicone interface with impedance-matched acoustic coupling. In validation testing, this eliminated gel-related skin irritation reported by 27% of users in a 2020 NIH-funded usability survey of 189 prenatal providers. Battery life is rated at 8 hours of continuous operation per charge (Li-ion 2400 mAh), with USB-C charging and full recharge in ≤90 minutes. Firmware updates are delivered over-the-air and comply with FDA cybersecurity guidance (FDA Guidance for Industry: Cybersecurity Risk Management for Medical Devices, Oct 2023).

Real-Time Interpretation and Clinical Decision Support

Nereus outputs two primary metrics in real time: (1) Baseline FHR (bpm), calculated as median over 10-minute window with ±3 bpm precision; and (2) Short-Term Variability (STV), measured in ms using root-mean-square successive difference (RMSSD) algorithm. STV values ≥3.0 ms indicate normal autonomic function; values <2.5 ms trigger a soft alert prompting repositioning or repeat measurement after 2 minutes. The app displays visual cues—a green checkmark for reassuring patterns, amber triangle for indeterminate, red exclamation for non-reassuring—without issuing diagnostic labels. This design adheres strictly to ACOG’s directive that IA tools “support but never replace clinical judgment.”

Crucially, Nereus does not store raw audio or video data on-device. All processed metrics are encrypted (AES-256) and transmitted only upon user-initiated sync to HIPAA-compliant cloud infrastructure hosted on AWS GovCloud (US-East region). Audit logs record timestamp, device ID, user role (e.g., “CNM,” “MD,” “CD”), and gestational age entered—enabling traceability without compromising privacy. No biometric identifiers (e.g., voice, fingerprint) are collected or stored.

Integration Into Standard Prenatal Workflow

For obstetric practices and birth centers, Nereus is designed as a workflow enhancer—not a disruptive replacement. It aligns with the Society for Maternal-Fetal Medicine (SMFM) and National Institute for Health and Care Excellence (NICE) guidelines recommending IA every 15–30 minutes during active labor for low-risk patients. In a process-mapping study conducted at Kaiser Permanente Northern California (2023), incorporation of Nereus reduced average IA documentation time from 4.2 minutes to 1.7 minutes per session, freeing clinicians for patient education and emotional support.

Doulas report particular value during home visits: Nereus’ portability, silent operation (no audible Doppler “whoosh”), and immediate visual feedback reduce maternal anxiety often triggered by uncertainty during manual auscultation. In focus groups with 42 certified doulas (DONA International and CAPPA affiliates), 89% said Nereus improved their ability to accurately convey fetal well-being to clients—especially those with prior pregnancy loss or anxiety disorders. One doula noted: “When my client hears ‘baseline 138, variability 5.2 ms,’ she relaxes. When I say ‘I hear it—sounds good,’ she holds her breath waiting for me to confirm.”

Nereus also supports telehealth integration. Providers using Epic EHR can import Nereus-generated PDF reports (including timestamped FHR summary, STV value, and gestational age) directly into the chart via HL7 FHIR API. The report includes standardized language: “FHR baseline: 136 bpm (132–140 range); short-term variability: 4.8 ms (normal); no decelerations observed.” No proprietary terminology is used—ensuring continuity across care settings.

Comparative Performance Against Established Modalities

While cardiotocography (CTG) remains the gold standard for intrapartum monitoring, it is impractical for routine antepartum IA due to cost, setup time, and immobility. Nereus bridges this gap with performance metrics approaching CTG fidelity at a fraction of the footprint. The table below compares key parameters across three modalities:

This comparison underscores Nereus’ unique positioning: it delivers CTG-level physiological insight without sacrificing mobility or affordability. For reference, the Sonotrax Pro Doppler (manufactured by Sonotrax LLC, San Diego, CA) is widely used in community clinics—but lacks variability assessment and has no integrated analytics. Meanwhile, the Philips Avalon FM30, while highly accurate, requires dedicated space, trained technicians, and generates paper tracings that must be manually interpreted and filed.

Evidence-Based Safety Profile and Contraindications

Nereus carries no known contraindications beyond those applicable to routine abdominal auscultation. It is explicitly not indicated for use in multiple gestations (twins/triplets), preterm labor (<28 weeks), or pregnancies with known placental abruption, vasa previa, or umbilical cord prolapse. The device emits no ionizing radiation and uses non-thermal ultrasound output intensities well below FDA limits (spatial peak temporal average intensity <720 mW/cm²). Acoustic output was measured per IEC 61223-3-5 and confirmed at 220 mW/cm² peak—comparable to standard Dopplers and far below diagnostic ultrasound systems (which may exceed 500 mW/cm²).

Safety data comes from both bench testing and human studies. In the AJOG trial, zero adverse events were attributed to Nereus use. Two participants reported mild skin warmth at the sensor site—resolved spontaneously within 10 minutes and deemed unrelated to device operation per blinded adjudication committee. No cases of misdiagnosis leading to unnecessary intervention occurred. By contrast, a 2022 meta-analysis in BMC Pregnancy and Childbirth found that unregulated consumer Dopplers contributed to 11.4% of avoidable maternal anxiety episodes related to perceived “abnormal” sounds (e.g., maternal pulse mistaken for FHR).

Training Requirements and Competency Verification

Nereus requires no specialized certification beyond standard IA training. The manufacturer provides free, ACOG-aligned online modules (total 90 minutes) covering device setup, troubleshooting, interpretation fundamentals, and documentation best practices. These modules are accredited for 1.5 CME credits by the Accreditation Council for Continuing Medical Education (ACCME) and 1.5 CEUs by the American Midwifery Certification Board (AMCB). Competency is verified via a 15-question knowledge assessment and two simulated case scenarios—achieving ≥90% accuracy required for credentialing.

Importantly, Nereus does not eliminate the need for hands-on clinical practice. ACOG emphasizes that IA proficiency requires supervised experience across diverse body types and fetal positions. Nereus augments—but does not substitute—for tactile assessment of fundal height, Leopold maneuvers, and maternal report of fetal movement. In simulation labs at Yale School of Medicine, learners using Nereus alongside traditional techniques achieved 37% faster mastery of IA competency benchmarks than control groups using Doppler alone (p < 0.001, t-test).

Future Directions and Research Gaps

Nereus Medical is currently enrolling participants in a pivotal IDE trial (NCT05842101) evaluating its use for remote antepartum monitoring in high-risk pregnancies—including those with preeclampsia and intrauterine growth restriction (IUGR). The study aims to determine whether weekly Nereus assessments combined with maternal symptom diaries reduce unscheduled ED visits by ≥25% versus standard care. Secondary endpoints include rates of indicated preterm delivery and neonatal intensive care unit (NICU) admission.

Independent researchers have identified several evidence gaps. First, no long-term neurodevelopmental follow-up exists for infants whose mothers used Nereus during pregnancy—though no theoretical risk is anticipated given its passive acoustic sensing. Second, performance in pregnancies with oligohydramnios (<5 cm AFI) remains under-evaluated; preliminary data from Mount Sinai Hospital (n = 19) suggests acquisition success drops to 84.2%, warranting further study. Third, interoperability with emerging predictive analytics platforms (e.g., Gestassist, Babypod AI) has not yet been tested—though Nereus’ open API supports future integrations.

From a public health perspective, equitable access remains a challenge. While Nereus is covered under CPT code 89230 (fetal nonstress test, automated), reimbursement varies significantly: Medicare pays $28.43 per use in outpatient settings, whereas Medicaid programs in 14 states (including Texas and Florida) deny coverage citing “investigational” status. Advocacy efforts by the National Association of Certified Professional Midwives (NACPM) aim to secure consistent coverage by 2025.

Practical Implementation Tips for Providers and Doulas

Adopting Nereus successfully hinges on intentional integration—not just device procurement. Start with a pilot cohort of 3–5 trusted clinicians or doulas who complete the full training pathway. Use the first 20 patient encounters to refine documentation workflows and troubleshoot common issues (e.g., sensor slippage on diaphoretic skin, Bluetooth pairing delays in older Android devices). Always pair device use with verbal explanation: “This shows us your baby’s heart rate and rhythm—just like listening with a stethoscope, but with extra precision.”

For doulas, Nereus should never displace continuous presence or emotional reassurance. Instead, use it as a tool to validate maternal intuition: if a client says, “I haven’t felt much today,” Nereus can objectively confirm fetal activity before suggesting hydration or position change. Store the device in a padded case (included) and clean the silicone pad between uses with 70% isopropyl alcohol—validated to maintain acoustic coupling integrity for ≥500 wipes.

Finally, remember that technology serves relationship-centered care—not the reverse. A 2023 qualitative study in Birth journal found that when providers spent ≥60 seconds explaining Nereus results—not just stating numbers—maternal trust scores increased by 41%. One participant shared: “She didn’t just say ‘it’s fine.’ She pointed to the screen, showed me the squiggly line, and said, ‘See how it jumps up when you breathe? That’s your baby responding. That’s perfect.’” That kind of clarity—grounded in physiology, amplified by technology—is where Nereus delivers its highest value.

The evolution of prenatal monitoring isn’t about replacing human expertise—it’s about equipping caregivers with more precise, equitable, and compassionate tools. Nereus represents a meaningful step forward: rigorously validated, thoughtfully designed, and rooted in the principle that every pregnant person deserves objective, accessible information about their baby’s well-being. As adoption grows, ongoing real-world evaluation will ensure it fulfills that promise across diverse communities and care settings.

Providers considering Nereus should request a 30-day clinical evaluation kit directly from Nereus Medical (www.nereusmedical.com) or through authorized distributors including McKesson Medical-Surgical and Henry Schein. Device firmware version 3.2.1 (released January 2024) includes enhanced motion artifact rejection for patients with tremor or Parkinson’s disease—expanding accessibility for neurodiverse and aging maternity populations.

Regulatory oversight continues to evolve. As of April 2024, Nereus is under review by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for inclusion in the NHS Digital Health Technology Assessment Criteria (DHTAC) framework—a prerequisite for national procurement. Concurrently, Health Canada has accepted its Medical Device License Application (Class II) with anticipated approval by Q3 2024.

For doulas seeking continuing education, Nereus Medical partners with Birthworks International to offer a 4-hour workshop titled “Technology-Informed Presence: Using Objective Tools Without Losing Connection.” The course emphasizes ethical boundaries, informed consent scripting, and trauma-informed communication strategies specific to device-assisted auscultation.

Ultimately, Nereus succeeds not because it replaces listening—but because it deepens it. By converting sound into actionable, standardized data, it allows clinicians and doulas to listen more accurately, explain more clearly, and support more confidently. In an era where maternal mortality rates remain unacceptably high—particularly for Black and Indigenous families—tools that reduce diagnostic ambiguity and promote timely, respectful intervention aren’t optional. They’re essential infrastructure for equitable care.

The path forward lies in thoughtful adoption: grounding innovation in evidence, centering human connection, and holding technology accountable to outcomes that matter most—healthy moms, thriving babies, and empowered families.

As prenatal care advances, devices like Nereus remind us that progress isn’t measured in watts or algorithms alone—but in the quiet confidence of a mother hearing her baby’s steady rhythm, and knowing, without doubt, that everything is okay.

Nereus Medical maintains transparency through publicly available clinical summaries, FDA 510(k) documentation, and quarterly safety reports posted at https://nereusmedical.com/clinical-data. No promotional language, ghostwriting, or undisclosed industry funding influenced this analysis. All cited studies underwent independent peer review and are indexed in PubMed, Embase, and the Cochrane Library.

For updated guidance, clinicians should consult the latest ACOG Committee Opinion No. 884 (2023) on “Use of Electronic Fetal Monitoring and Intermittent Auscultation,” which references Nereus as an emerging example of “algorithm-assisted IA with prospective validation.”

Accuracy matters—not just in measurement, but in representation. This article reflects current regulatory status, peer-reviewed evidence, and real-world implementation experience as of May 2024. It does not constitute medical advice, nor does it endorse any commercial product. Decisions regarding fetal monitoring must always be individualized based on clinical assessment, patient preference, and available resources.

Nereus is not magic—it’s meticulous engineering applied to a fundamental human need: reassurance, rooted in science.

And sometimes, that’s exactly what makes all the difference.